Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Accured Expenses (2018 - 2025)

UroGen Pharma (URGN) has disclosed Change in Accured Expenses for 8 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 732.79% year-over-year to $1.5 million, compared with a TTM value of $286000.0 through Dec 2025, up 217.21%, and an annual FY2025 reading of $286000.0, up 217.21% over the prior year.
  • Change in Accured Expenses was $1.5 million for Q4 2025 at UroGen Pharma, up from -$2.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.8 million in Q2 2024 and bottomed at -$5.8 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $416888.9, with a median of $779500.0 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 901.79% in 2024, while the deepest fall reached 222.79% in 2024.
  • Year by year, Change in Accured Expenses stood at $966000.0 in 2021, then surged by 108.39% to $2.0 million in 2022, then skyrocketed by 111.62% to $4.3 million in 2023, then crashed by 105.73% to -$244000.0 in 2024, then soared by 732.79% to $1.5 million in 2025.
  • Business Quant data shows Change in Accured Expenses for URGN at $1.5 million in Q4 2025, -$2.3 million in Q3 2025, and $593000.0 in Q2 2025.